Status:
COMPLETED
Observational Study of Kibow Biotics in Dialysis Patients
Lead Sponsor:
Kibow Pharma
Collaborating Sponsors:
Thomas Jefferson University
Conditions:
Chronic Kidney Failure
Eligibility:
All Genders
18-75 years
Brief Summary
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM". However, it is also refe...
Detailed Description
Probiotics are increasingly utilized clinically. As their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number ...
Eligibility Criteria
Inclusion
- Currently on hemodialysis
- 18 to 75 years of age
- Willing to give informed consent
- Baseline serum creatinine \>2.5 mg/dL
Exclusion
- Pregnant or nursing women
- Refusal to sign the informed consent form
- Documented to have HIV/AIDS/Liver disease
- Active dependency on drugs or alcohol
- Currently on anticoagulant therapy
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01450670
Start Date
May 1 2011
End Date
July 1 2012
Last Update
August 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107